Allergy Shot Maintenance Schedule: Dose, Interval, and Duration

Per Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034), the SCIT maintenance schedule is every 2–4 weeks for 3–5 years once the target maintenance dose is reached. Most US clinics anchor on the 4-week (monthly) interval as the longest sustainable cadence — Cox 2011 does not endorse intervals longer than 4 weeks for adult environmental allergen SCIT. The maintenance dose is typically approximately 0.5 mL of the maintenance concentrate (red-cap 1:1 vial per the ACAAI mixing guide). Each maintenance visit requires the same mandatory 30-minute observation as build-up visits.

At the every-2-to-4-week maintenance interval, patients complete approximately 12–26 visits per year during the maintenance phase. Over a 3–5-year maintenance course, that equals roughly 42–130 lifetime maintenance visits — on top of the 24–28 build-up visits. This represents a substantial cumulative clinic burden. By comparison, FDA-approved SLIT tablets require only a single supervised first dose, with all subsequent daily doses self-administered at home. The cumulative clinic-visit difference is a key factor in patient adherence — only 43.9% of AIT patients who start SCIT ever reach the maintenance phase per Tkacz JP et al., Curr Med Res Opin 2021;37(6):957–965.

Yes — the mandatory 30-minute observation period per Cox 2011 PP3 applies to every SCIT injection, including maintenance. It does not relax at any phase of treatment. The rationale is that approximately 70% of fatal and systemic reactions onset within the first 30 minutes, and the one fatality per 23.3 million injection visits documented by Epstein TG et al. (PMID 23535092) is conditional on administration with epinephrine on hand. Some patients assume the observation period shortens in maintenance — this is a common and incorrect assumption.

Exceeding the maintenance interval triggers a dose-reduction protocol per Cox 2011 PP3 interval-based dose-adjustment tables. The general principle: the longer the gap, the more the dose must be reduced before returning to the target maintenance dose. A gap of a few days beyond the scheduled interval may be manageable without dose reduction at the allergist's discretion; a gap of several weeks typically requires stepping back by one or more dose levels. Patients should notify their allergist before any known scheduling gap so that a reduced-dose vial can be prepared. Repeating the prior lower dose once before resuming the target dose is the conservative and safe approach.

Durham SR, Walker SM, Varga EM et al., N Engl J Med 1999;341:468–475 demonstrated that 3 years of grass SCIT maintenance followed by randomized discontinuation produced sustained symptom remission for 4 years post-treatment. This durable remission — meaning the benefit persists without any ongoing treatment — is the central disease-modifying advantage of SCIT over symptomatic treatments. Patients who discontinue before completing 2–3 years of maintenance typically experience relapse within 12–18 months of stopping. PAT pediatric data (Jacobsen L et al., Allergy 2007;62:943–948, 10-year follow-up) extends the durability claim to prevention of new sensitizations and asthma progression in children.

Cox 2011 PP3 does not endorse intervals longer than 4 weeks for adult environmental allergen SCIT as a standard maintenance schedule. Some allergists may cautiously consider 5–6-week intervals for very stable patients who have been on maintenance for several years, but this is off-guideline practice. Hymenoptera venom immunotherapy (VIT) may be extended to 8-week intervals after 3–5 years of stable maintenance in some protocols. For environmental allergen SCIT, extending beyond monthly risks losing the immune tolerant state and may trigger a dose reduction at the next visit — effectively restarting part of the escalation process.

The maintenance dose per Cox 2011 PP3 is typically approximately 0.5 mL of the maintenance concentrate — the highest-concentration vial in the allergen extract series, labeled as the 1:1 v/v concentration and color-coded red in the ACAAI mixing guide scheme. This is the dose at which the immune system reliably maintains the tolerogenic state established during build-up. Your allergist will have titrated the extract concentration during build-up to reach a dose that produced clinical improvement without intolerable reactions. Patients should read the concentration on the vial label rather than relying on the color code — only 41% of US practices use the standard color-coding scheme per Prudenti 2023.